Philippines - English - FDA (Food And Drug Administration)

elanco philippines, inc.; distributor: elanco philippines, inc. - calcium , phosphorus , organic acids (vet.) - feed premix powder - formulation: each kilogram contains: calcium formate...... 360 g calcium lactate.......150 g calcium citrate........150 g phosphoric acid.......135 g citric acid..............60 g formic acid.........50 g lactic acid..........43 g sorbic acid.........30 g malic acid..........45 g

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - tralkoxydim - water dispersible granule - tralkoxydim cyclohexanediones active 400.0 g/kg - herbicide - barley | barley - see label for exceptions | cereal rye | triticale | wheat - annual or wimmera ryegrass | annual phalaris | lesser canary grass - suppression | paradoxa grass - suppression | wild oat | canary grass | rigid ryegrass | wimmera ryegrass

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

upl australia pty ltd - mancozeb - wettable powder - mancozeb carbamate-dithiocarbamate active 800.0 g/kg - fungicide - almond | apple | apricot | banana | bean | beetroot | broad bean | broccoli | brussels sprouts | cabbage | capsicum or pepper | - alternaria leaf blight or spot blight | alternaria spot | angular leaf spot - p. griseola | anthracnose | anthracnose on bean | anthracnose on cucurbit | anthracnose on mango | bitter rot | black pit | black spot - colletotrichum acutatum | black spot on citrus | black spot on rose | black spot/scab in apple/pear | blight | blue mould on tobacco | botrytis leaf spot or corm collar rot | brown citrus rust mite | brown rot | brown spot on passionfruit | brown spot on tobacco | cercospora leaf spot | cercospora leaf spot - banana | chocolate spot on bean | citrus bud mite | citrus rust mite or maori mite | cordana leaf spot | downy mildew | downy mildew on cucurbit | downy mildew on lettuce | early blight (target spot) | fly speck | freckle or scab on stone fruit | frog eye spot on tobacco | fruit freckle | fusarium seedpiece rot | fusarium spp. | grey leaf spot - pyricularia grisea | grey mould - botrytis cinerea | gummy stem blight on cucurbit | helminthosporium disease | late blight or irish blight | leaf bli

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

medicamen biotech ltd. - carvedilol - tablets - 6,25mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

medicamen biotech ltd. - carvedilol - tablets - 12,5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

medicamen biotech ltd. - carvedilol - tablets - 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; indigo carmine; iron oxide black; titanium dioxide; pregelatinised maize starch - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Kenya - English - Pharmacy and Poisons Board

wockhardt limited wockhardt towers bandra-kurla complex bandra (e) - azithromycin capsules usp 250mg - capsule, hard - 250mg - antibacterials for systemic use: macrolides

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - capsule, hard - excipient ingredients: meglumine; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 2.5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; meglumine; titanium dioxide; quinoline yellow; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.